|
|
|
|
* ºÐ½Ç¹° ½Å°í * info@kobia.kr * »ó¼¼ ³»¿ëÀº º» ´º½º·¹ÅÍ ÇÏ´Ü Çùȸ ¼Ò½Ä¿¡¼ È®ÀÎÇϼ¼¿ä * |
|
½ÄÇ°ÀǾàÇ°¾ÈÀüó ¼Ò½Ä |
º¸µµ
ÀÚ·á |
¹ÙÀÌ¿ÀÀǾàÇ° »ê¾÷¹ßÀü Àü·«±âȹ´Ü ¿öÅ©¼ó / Á¦2Â÷ ¹ÙÀÌ¿ÀÀǾàÇ° Çã°¡‧½É»ç ¼³¸íȸ °³ÃÖ |
¡®¹ÙÀÌ¿ÀÀǾàÇ° »ê¾÷¹ßÀü Àü·«±âȹ´Ü(Dynamic BIO)¡¯ ¿öÅ©¼óÀ» ¿À´Â 11¿ù 28ÀÏ ±×·£µåÄÁº¥¼Ç¼¾ÅÍ(¼¿ï½Ã ¿µµîÆ÷±¸ ¼ÒÀç)¿¡¼ °³ÃֵǾú´Ù. ¡¯17³â ´ÙÀ̳ª¹Í¹ÙÀÌ¿À ¿î¿µ °á°ú¸¦ °øÀ¯ÇÏ°í ¹ÙÀÌ¿ÀÀǾàÇ° »ê¾÷¹ßÀü ¹æ¾ÈÀ» ³íÀÇÇϱâ À§ÇØ ¸¶·ÃµÇ¾úÀ¸¸ç, ¹ÙÀÌ¿ÀÀǾàÇ° Á¦¾à»ç µî ¾à 167¸íÀÌ Âü¼®Çß´Ù. ÁÖ¿ä ³»¿ëÀº ¡ã¡®17³âµµ ´ÙÀ̳ª¹Í¹ÙÀÌ¿À ¿î¿µ°á°ú ¹ßÇ¥ ¡ãºÐ°úº° Åä·Ðȸ ¹× ¡®¼ÒÅëÀÇ À塯 ¹Î¿ø ´ë¸é»ó´ã ¡ã¹ÙÀÌ¿ÀÀǾàÇ° Á¤Ã¥¼³¸íȸ µîÀ̾úÀ¸¸ç, ¹ÙÀÌ¿ÀÀǾàÇ° ºÐ¾ß ¹Î¿øÀΰú ½Ä¾àó °£ ´ë¸é»ó´ãÀ» ÅëÇØ ¹Î¿øÀÎÀÇ ¾Ö·Î»çÇ×À» ÇØ°áÇÏ´Â ¡®¼ÒÅëÀÇ À塯 ÇÁ·Î±×·¥µµ »õ·Ó°Ô ¿î¿µµÇ¾ú´Ù.
¡Ø ´ÙÀ̳ª¹Í¹ÙÀÌ¿À : ¹ÙÀÌ¿ÀÀǾàÇ° »ê¾÷À» Áö¿øÇÏ°í Á¦¾à±â¾÷°úÀÇ ¼ÒÅëÀ» °ÈÇϱâ À§ÇÑ »ê¾÷°è¡¤Çа衤½Ä¾àó ÇùÀÇü·Î Á¤Ã¥, Á¦µµ °³¼± µîÀ» ³íÀÇÇÏ°íÀÚ ¹ÙÀÌ¿ÀÀǾàÇ° ºÐ¾ß Àü¹®°¡ µîÀÌ Âü¿©ÇÑ´Ù. (´ÙÀ̳ª¹Í¹ÙÀÌ¿À ºÐ°ú ¼Ò°³ ¹× Âü¿© ½Åû Click)
¢º 2017³â ´ÙÀ̳ª¹Í ¹ÙÀÌ¿À ¿öÅ©¼ó ³»¿ë º¸·¯°¡±â
¢º ¹ÙÀÌ¿ÀÀǾàÇ° Á¤Ã¥ ÃßÁøÇöȲ º¸·¯°¡±â
¿öÅ©¼ó ÀÌÈÄ¿¡´Â ¡®¹ÙÀÌ¿ÀÀǾàÇ° Çã°¡¡¤½É»ç ¼³¸íȸ(Bio- Update)¡¯°¡ °³ÃÖµÇ¾î ¹ÙÀÌ¿ÀÀǾàÇ° Çã°¡½É»ç µî °ü·Ã ±ÔÁ¤ ¼³¸íÀÌ À̾îÁ³´Ù. ÁÖ¿ä ³»¿ëÀº ¡ã¡®17³â ¹ÙÀÌ¿ÀÀǾàÇ° Çã°¡½É»ç ÁÖ¿ä¾÷¹« ÃßÁøÇöȲ ¡ã¡¯17³â ¹ÙÀÌ¿ÀÀǾàÇ° Á¦¡¤°³Á¤ °¡À̵å¶óÀÎ ¼³¸í(»ý¹°ÇÐÀûÁ¦Á¦, À¯ÀüÀÚÀçÁ¶ÇÕÀǾàÇ°, ¼¼Æ÷¡¤À¯ÀüÀÚÄ¡·áÁ¦) ¡ãÁúÀÇ ÀÀ´ä µîÀÌ´Ù. ¹ßÇ¥ÀÚ·á´Â ÃßÈÄ ½Ä¾àó ȨÆäÀÌÁö¿¡ ¾÷·Îµå µÉ ¿¹Á¤ÀÌ´Ù.
¢º °ü·Ã±â»ç È®ÀÎ
|
|
¹Î¿øÀÎ
¾È³»¼ |
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º ¹é½ÅÀÇ Çã°¡½É»ç °¡À̵å¶óÀÎ |
¡®ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV)¡¯ ¹é½ÅÀÇ Ç°Áú°ú ¾ÈÀü¼ºÀ¯È¿¼º ½É»ç ½Ã °í·Á»çÇ׿¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ ´ãÀº ¡®ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º ¹é½ÅÀÇ Çã°¡½É»ç °¡À̵å¶óÀΡ¯À» Á¦Á¤¹ß°£Çß´Ù.
¡Ø ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV, Human Papilloma Virus) : HPV´Â »ý½Ä±â °¨¿°À» ÀÏÀ¸Å°´Â °¡Àå ÈçÇÑ ¿øÀÎ º´¿øü Áß Çϳª·Î, Áö¼Ó °¨¿° ½Ã HPV °ü·Ã ¾Ï(ÀڱðæºÎ¾Ï, ¿ÜÀ½ºÎ¾Ï, Ç×¹®¾Ï, µÎ°æºÎ¾Ï µî)°ú ±× Àü¾Ïº´º¯, »ý½Ä±â »ç¸¶±Í, Àç¹ß¼º È£Èí±â À¯µÎÁ¾Áõ°ú °°Àº ÁúȯÀ» À¯¹ßÇϸç, ¿¹¹æÁ¢Á¾À» ÅëÇØ ¹é½Å¿¡ Æ÷ÇÔµÈ À¯Çü¿¡ ÀÇÇÑ HPV °¨¿°À» ¿¹¹æÇÒ ¼ö ÀÖÀ½
À̹ø °¡À̵å¶óÀÎÀº HPV ¹é½ÅÀÇ °³¹ß °úÁ¤ Àü¹Ý¿¡ ´ëÇÑ ÇØ¿Ü ÃֽŠÁ¤º¸¸¦ Á¦°øÇÏ¿© ±¹³» °³¹ß HPV ¹é½ÅÀÇ ½Å¼ÓÇÑ Çã°¡¿Í Á¦Ç°È¿¡ µµ¿òÀ» ÁÖ±â À§ÇØ ¸¶·ÃµÇ¾úÀ¸¸ç ÁÖ¿ä ³»¿ëÀº ¡ã¹é½Å Á¦Á¶ ½Ã °í·Á»çÇ× ¡ãÁ¦Á¶ ´Ü°è º° Ç°Áú °ü¸® ¡ãºñÀÓ»ó ¹× ÀÓ»ó Æò°¡ ¹æ¹ý ¡ã½ÃÆÇÈÄ Æò°¡¿¡ ´ëÇÑ °í·Á»çÇ× µîÀÌ´Ù.
¢º º¸µµÀÚ·á È®ÀÎ
¢º °¡À̵å¶óÀÎ Àü¹® È®ÀÎ |
|
±³À°
¾Ë¸² |
¡®¹ÙÀÌ¿À½Ã¹Ð·¯¡¯ °ü·Ã ±¹Á¦Àû ½É»ç±âÁØ ¸¶·Ã - ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀûÀÀÁõ ¿Ü»ðÀ» À§ÇÑ °úÇÐÀû Áöħ¼ °ø°³ |
½ÄÇ°ÀǾàÇ°¾ÈÀüó(óÀå ·ù¿µÁø) ½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿øÀº ±¹Á¦ÀǾàÇ°±ÔÁ¦ÀÚÆ÷·³(IPRF) ¹ÙÀÌ¿À½Ã¹Ð·¯ ¿öÅ·±×·ì ÀÇÀå±¹À¸·Î¼ ¡®¹ÙÀÌ¿À½Ã¹Ð·¯ ÀûÀÀÁõ ¿Ü»ðÀ» À§ÇÑ °úÇÐÀû Áöħ¼(¿µ¹®)¡¯À» ¸¶·ÃÇÏ¿© ±¹Á¦ÀǾàÇ°±ÔÁ¦ÀÚÆ÷·³(IPRF) ȨÆäÀÌÁö ¹× ½Ä¾àó ¿µ¹® ȨÆäÀÌÁö¿¡ °Ô½ÃÇß´Ù.
¡Ø IPRF(International Pharmaceutical Regulators Forum) : ICH ±¹Á¦Çù·ÂÀ§¿øȸ Áß ¹Ì±¹, EU, ÀϺ» µî 11°³ ±ÔÁ¦´ç±¹, APEC µî 5°³ Áö¿ª´ëÇ¥ ¹× WHOÀÇ ±ÔÁ¦´ç±¹ÀÚ·Î ±¸¼ºµÈ ȸÀÇü·Î ÀǾàÇ° ±ÔÁ¦ °ü·Ã Á¤º¸±³È¯ ¹× »óÈ£Çù·ÂÀ» À§ÇØ 2008³â 6¿ùºÎÅÍ ½Å¼³ ¿î¿µ Áß
À̹ø Áöħ¼´Â ¹Ì±¹, À¯·´ µî °¢ ±¹°¡º°·Î ¿î¿µµÇ°í ÀÖ´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀûÀÀÁõ ¿Ü»ð °¡À̵å¶óÀο¡ ´ëÇØ Ã³À½À¸·Î ±¹Á¦ÀûÀ¸·Î ÅëÀÏµÈ ±âÁØÀ» ¸¶·ÃÇÑ °ÍÀ¸·Î ±¹³»¡¤¿Ü ±ÔÁ¦±â°ü, Á¦¾à»ç µîÀÇ ÀÇ°ßÀ» ¼ö·ÅÇÑ ÈÄ IPRF ¹ÙÀÌ¿À½Ã¹Ð·¯ ¿öÅ·±×·ì°ú °ü¸®À§¿øȸ ½ÂÀÎ ÀýÂ÷¸¦ °ÅÃÄ ÃÖÁ¾ È®Á¤µÇ¾ú´Ù. ÁÖ¿ä ³»¿ëÀº ¡ã¹ÙÀÌ¿À½Ã¹Ð·¯ Ç°¸ñ ÀûÀÀÁõ ¿Ü»ð½Ã °í·Á»çÇ× ¡ã¹Ì±¹, À¯·´, ÀϺ» µî ±¹°¡º° °ü·Ã °¡À̵å¶óÀÎ ºñ±³ ºÐ¼® ¡ã±¹°¡º° Ç°¸ñº° ÀûÀÀÁõ ¿Ü»ð Àû¿ë ½É»ç»ç·Ê ºñ±³ ºÐ¼® µîÀÌ´Ù.
¡Ø ÀûÀÀÁõ ¿Ü»ð ¿¹½Ã) ¿À¸®Áö³ÎÀǾàÇ°ÀÇ È¿´É¡¤È¿°ú°¡ ·ù¸¶Æ¼½º¼º °üÀý¿°, °Ç¼±¼º°üÀý¿°, Å©·Ðº´ÀÌ°í ¹ÙÀÌ¿À½Ã¹Ð·¯¿Í ¿À¸®Áö³ÎÀǾàÇ°°£ ºñ±³ÀÓ»óÀ» ÅëÇØ ´ëÇ¥ÀûÀÀÁõÀÎ ·ù¸¶Æ¼½º¼º °üÀý¿°¿¡ ´ëÇÑ ¾ÈÀü¼º¡¤À¯È¿¼ºÀÌ ÀÔÁõµÈ °æ¿ì °Ç¼±¼º°üÀý¿°, Å©·Ðº´¿¡ ´ëÇÑ º°µµ ÀÓ»ó½ÃÇè¾øÀÌ È¿´É¡¤È¿°ú ÀÎÁ¤
¢º º¸µµÀÚ·á È®ÀÎ
¢º Áöħ¼ Àü¹® È®ÀÎ |
|
±âŸ
°í½Ã |
Á¦°³Á¤°í½Ã ¸ñ·Ï È®ÀÎ |
|
|
|
|
±¹³» ÀÓ»ó ÇöȲ |
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
½ÃÇè
Á¦¸ñ |
´Ü°è |
¾ÆÀÌÄÜ
Ŭ¸®´ÏÄÃ
¸®¼Ä¡
ÄÚ¸®¾Æ (À¯) |
20171129 |
ÁøÇ༺ ¾Ç¼º Á¾¾ç ȯÀÚ¸¦ ´ë»óÀ¸·Î REGN3767(Ç×-LAG-3 mAb) ´Üµ¶ Åõ¿© ¶Ç´Â REGN2810(Ç×-PD-1 mAb)°ú º´¿ë Åõ¿©ÀÇ ¾ÈÀü¼º, ³»¾à¼º, È°¼º ¹× ¾à¹°µ¿ÅÂÇп¡ ´ëÇÑ Á¦1»ó, °ø°³, ¿ë·® Áõ°¡ ¹× ÄÚȣƮ È®Àå ÃÖÃÊ ÀÎü Àû¿ë ÀÓ»ó½ÃÇè |
1»ó |
REGN3767
REGN2810 |
Äڹݽº
ÄÚ¸®¾Æ
¼ºñ½º
À¯ÇÑȸ»ç |
20171122 |
±¹¼Ò ÁøÇ༺ ÀýÁ¦ ºÒ°¡ ¶Ç´Â ÀüÀ̼º À§¾Ï ¶Ç´Â À§½Äµµ Á¢ÇպΠ¾Ï(¸ð¸£Æä¿ì½º À§¾Ï) ȯÀÚ¿¡¼ ¿©·¯ °¡Áö ¸é¿ª ¿ä¹ý ±â¹Ý Ä¡·á º´ÇÕÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» Æò°¡ÇÏ´Â Á¦Ib/II»ó, °ø°³, ´Ù±â°ü, ¹«ÀÛÀ§ ¹èÁ¤, Æ÷°ý ÀÓ»ó ½ÃÇè |
1/2»ó |
¾ÆÅ×Á¹¸®ÁÖ¸¿,
ÄÚºñ¸ÞƼ´Õ,
PEGPH20,
BL-8040,
¸®³ª±Û¸³Æ¾ |
ÄÚ¿À·Õ
»ý¸í°úÇÐ
ÁÖ½Äȸ»ç |
20171122 |
Kellgren & Lawrence Grade 2·Î Áø´Ü ¹ÞÀº ¹«¸ °ñ°üÀý¿° ȯÀÚ¸¦ ´ë»óÀ¸·Î ¡®Àκ¸»çÄÉÀÌÁÖ(Invossa K Injection)¡¯ÀÇ À¯È¿¼º ¹× ¾ÈÀü¼º Æò°¡¸¦ À§ÇÑ ´Ù±â°ü, ¹«ÀÛÀ§¹èÁ¤, º´Ç༳°è, À§¾à ´ëÁ¶, ÀÌÁß´«°¡¸², Á¦3»ó ÀÓ»ó½ÃÇè |
3»ó |
Àκ¸»ç
ÄÉÀÌÁÖ |
Çѱ¹
¿¥¿¡½ºµð
(À¯) |
20171122 |
Á¦III-IVA±â ÀýÁ¦ °¡´É ±¹¼Ò±¹ºÎ ÁøÇ༺ µÎ°æºÎ ÆíÆò¼¼Æ÷¾ÏÁ¾(Locoregionally Advanced Head and Neck Squamous Cell Carcinoma, LA HNSCC)¿¡ ´ëÇÑ ½Åº¸Á¶ ¿ä¹ýÀ¸·Î¼ÀÇ Pembrolizumab°ú º¸Á¶ ¿ä¹ýÀ¸·Î¼ Ç¥ÁØÄ¡·á¿Í º´¿ëÇÑ PembrolizumabÀ» Æò°¡ÇÏ´Â Á¦III»ó, ¹«ÀÛÀ§¹èÁ¤, ¶óº§-°ø°³ ÀÓ»ó½ÃÇè |
3»ó |
MK-3475 |
|
|
ÇØ¿ÜÀǾàÇ° Çã°¡ÇöȲ |
¹Ì±¹ |
|
|
|
Drug name |
Active Ingredients |
Submission Classification |
Company |
Approval date |
HEMLIBRA
BLA #761083 |
EMICIZUMAB |
- |
GENENTECH INC |
11/16/2017 |
PALONOSETRON
NDA #208109 |
PALONOSETRON HYDROCHLORIDE |
½ÅÁ¦Çü ¶Ç´Â ½ÅÁ¦Á¶¿ø |
FRESENIUS KABI USA |
11/21/2017 |
JULUCA
NDA #210192 |
DOLUTEGRAVIR;RILPIVIRINE |
½Åº¹ÇÕ |
VIIV HLTHCARE |
11/21/2017 |
|
|
À¯·´ |
|
|
|
Name |
Active Substance |
Therapeutic Area |
Date of Authorisation / Refusal |
Miglustat Gen.Orph |
miglustat |
Gaucher Disease |
10/11/2017 |
Zejula |
niraparib tosylate monohydrate |
Fallopian Tube Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms |
16/11/2017 |
|
|
ÇؿܹÙÀÌ¿ÀÀǾàÇ° ÀÓ»óÇöȲ |
¹Ì±¹ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor |
Phases |
NCT03353597 |
Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects |
Aging |
Biological: Plasma Transfusion |
Chandra Duggirala
Fountain Labs, Inc. |
Phase 1
Phase 2 |
NCT03352765 |
Rituximab, Bendamustine and Melphalan Chemo-immunotherapy Followed by Reinfusion of One's Own Stem Cell for Treatment of B-cell Lymphoma in Elderly Patients |
Lymphoma |
Drug: rituximab
Drug: bendamustine
Drug: melphalan
Procedure:
Autologous Stem
Cell Transplantation (ASCT) |
Memorial Sloan Kettering Cancer Center |
Phase 1
Phase 2 |
NCT03355560 |
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy |
Head and
Neck Cancer |
Drug: Nivolumab |
Sulsau-Ul Haque
Bristol-Myers Squibb
University of Cincinnati |
Phase 2 |
NCT03355365 |
Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis |
Multiple Sclerosis |
Biological:
intrathecal MSC-NP injection
Other: lumbar puncture placebo control |
Tisch Multiple Sclerosis Research Center of New York |
Phase 2 |
NCT03354390 |
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma |
Kidney Cancer |
Biological:
cell infusion |
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health Clinical Center (CC) |
Phase 1 |
NCT03352466 |
NasoShield Study of Safety and Immunogenicity |
Healthy Volunteers |
Biological: NasoShield
Biological:BioThrax
Other: Placebo |
Altimmune, Inc. |
Phase 1 |
NCT03349983 |
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury) |
Safety Issues |
Biological: MVA-BN-Brachyury/ FPV-Brachyury |
Bavarian Nordic |
Phase 1 |
NCT03349528 |
Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression |
Bipolar Depression |
Biological: Probiotic Supplement
Biological:
Inert Compound |
Sheppard Pratt Health System |
Phase 2 |
NCT03354728 |
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant |
Cytomegalovirus Positive
Hematopoietic Cell Transplantation Recipient |
Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Other: Laboratory Biomarker Analysis |
City of Hope Medical Center |
Phase 1
Phase 2 |
NCT03349645 |
An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee |
Severe Osteoarthritis of the Knee |
Biological: Ampion |
Ampio Pharmaceuticals. Inc. |
Phase 3 |
NCT03349710 |
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer |
Squamous Cell Carcinoma of the Head and Neck |
Biological: Nivolumab
Biological: Cetuximab
Drug: Placebo
Drug: Cisplatin |
Bristol-Myers Squibb
ONO Pharmaceutical Co. |
Phase 3 |
NCT03353675 |
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) |
NSCLC |
Biological: TG4010
Drug: Chemotherapy
Drug: Nivolumab |
Transgene
Bristol-Myers Squibb |
Phase 2 |
|
|
À¯·´ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
ºñ°í |
NCT03354962 |
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors |
Melanoma |
Combination Product: Nivolumab + Ipilimumab
Combination Product: Combined treatment schema |
Institut Claudius Regaud |
Phase 1
Phase 2 |
ÇÁ¶û½º |
NCT03353831 |
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer |
Recurrent Ovarian Carcinoma |
Drug: Bevacizumab
Drug: Atezolizumab
Drug: Chemotherapy
Drug: Placebos |
AGO Research GmbH|Hoffmann-La Roche |
Phase 3 |
µ¶ÀÏ |
NCT03352934 |
Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy |
Cancer |
Drug: Avelumab |
Johannes Gutenberg University Mainz|Merck KGaA |
Phase 2 |
µ¶ÀÏ |
NCT03351361 |
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer |
Advanced Non Small Cell Lung Cancer |
Drug: Nivolumab + Ipilimumab
Drug: Chemotherapy |
Rennes University Hospital |
Phase 3 |
ÇÁ¶û½º |
NCT03350126 |
Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab |
Metastatic Cancer Colorectal |
Drug: Ipilimumab 200 MG in 40 ML Injection
Drug: Nivolumab 10 MG/ML |
GERCOR - Multidisciplinary Oncology Cooperative Group|Bristol-Myers Squibb |
Phase 2 |
ÇÁ¶û½º |
NCT03353675 |
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) |
NSCLC |
Biological: TG4010
Drug: Chemotherapy
Drug: Nivolumab |
Transgene
Bristol-Myers Squibb |
Phase 2 |
ÇÁ¶û½º |
|
|
Áß±¹ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor/
Collaborators |
Phases |
NCT03353428 |
Intervention of Engineered Immune Effector T Cells Against Lung Cancer |
Lung Cancer|NSCLC |
Biological: LC-CTLs |
Shenzhen Geno-Immune Medical Institute |
Phase 1
Phase 2 |
NCT03351855 |
HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV |
Human Papilloma Virus |
Biological: HPV-CTLs |
Shenzhen Geno-Immune Medical Institute |
Phase 1
Phase 2 |
NCT03350633 |
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders |
Neuromyelitis
Optica Spectrum Disorders
Neuromyelitis Optica |
Drug: Tocilizumab Injection|Drug: Azathioprine |
Tianjin Medical University General Hospital |
Phase 2
Phase 3 |
NCT03355859 |
Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma |
Non Hodgkin Lymphoma |
Biological: JWCAR029 |
Zhao Weili|MingJu Therapeutics (Shanghai) Co., Ltd|Ruijin Hospital |
Phase 1 |
NCT03349255 |
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma |
Hepatocellular Carcinoma
Liver Cancer
Liver Neoplasms
Metastatic Liver Cancer |
Biological: autologous ET1402L1-CART cells |
Aeon Therapeutics (Shanghai) Co., Ltd.|Renmin Hospital of Wuhan University|Eureka Therapeutics Inc. |
Phase 1 |
|
|
Çùȸ ¼Ò½Ä |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|